Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML
Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.
Related Articles
Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization The Ohio State University James…
CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.
Home Page: Annals of Oncology
Published online: September 14, 2024 Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides…
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive NMIBC With CIS
Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.
Co-occurrence of ESR1m with other alterations
Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low…
MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors
Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.
Cancer: Vol 130, No 24
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBC
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and…
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.